Saltar al contenido
MilliporeSigma
  • Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria.

Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria.

Nucleic acids research (2011-07-05)
Olga Z Karicheva, Olga A Kolesnikova, Tom Schirtz, Mikhail Y Vysokikh, Anne-Marie Mager-Heckel, Anne Lombès, Abdeldjalil Boucheham, Igor A Krasheninnikov, Robert P Martin, Nina Entelis, Ivan Tarassov
RESUMEN

Mutations in human mitochondrial DNA are often associated with incurable human neuromuscular diseases. Among these mutations, an important number have been identified in tRNA genes, including 29 in the gene MT-TL1 coding for the tRNA(Leu(UUR)). The m.3243A>G mutation was described as the major cause of the MELAS syndrome (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes). This mutation was reported to reduce tRNA(Leu(UUR)) aminoacylation and modification of its anti-codon wobble position, which results in a defective mitochondrial protein synthesis and reduced activities of respiratory chain complexes. In the present study, we have tested whether the mitochondrial targeting of recombinant tRNAs bearing the identity elements for human mitochondrial leucyl-tRNA synthetase can rescue the phenotype caused by MELAS mutation in human transmitochondrial cybrid cells. We demonstrate that nuclear expression and mitochondrial targeting of specifically designed transgenic tRNAs results in an improvement of mitochondrial translation, increased levels of mitochondrial DNA-encoded respiratory complexes subunits, and significant rescue of respiration. These findings prove the possibility to direct tRNAs with changed aminoacylation specificities into mitochondria, thus extending the potential therapeutic strategy of allotopic expression to address mitochondrial disorders.

MATERIALES
Referencia del producto
Marca
Descripción del producto

SAFC
L-Glutamina solution, 29.23 mg/mL in saline, solution, suitable for cell culture
Sigma-Aldrich
L-Metionina, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 99.0-101.0%
SAFC
L-Metionina
Sigma-Aldrich
L-Metionina, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
D-Methionine, ≥98% (HPLC)
Sigma-Aldrich
L-Metionina, reagent grade, ≥98% (HPLC)
Supelco
L-Metionina, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Metionina, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Metionina, SAJ special grade, ≥98.5%